NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players
Read the full report: https://www.reportlinker.com/p05627266
SummaryExosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine, cerebrospinal fluid (CSF) as well as in in vitro cell culture.
These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right.Exosome can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier (BBB) for the delivery of central nervous system (CNS) therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects. Research within this area remains in the nascent stages, though several clinical studies have been registered within the field.Although research within the exosome field is in the early stages, the area boasts a broad and diverse pipeline consisting of 22 active products. The majority of these products are within the Preclinical stage of development, and are indicated for the treatment of cancer. Other therapeutic areas strongly represented in this pipeline include the CNS and cardiovascular therapy areas. The clinical trials landscape for exosome therapies is similarly diverse. Since 2006, a total of 124 clinical trials have taken place.As a result, interest and investment within the field of exosome therapies have been increasing steadily over the past 10 years. Currently there is only one product approved for use on the market, the Exodx Prostate Intelliscore diagnostic test for prostate cancer, developed and marketed by Exosome Diagnostics.There are a range of companies within the pipeline landscape, most of which have only become established within the past few years. One of the leading companies in this sector is Capricor Therapeutics. The company is forecast to make a profit on the market with a net revenue of $333 million forecast for 2024 attributable to the anticipated successful development of its key product CAP-1002."Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players", explores the application of Exosome technologies within the pharmaceutical and healthcare industries.This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.Scope- What are the features of the exosome lifecycle?- How are therapeutic exosomes prepared?- How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?- Which companies are investing in exosome technologies?- How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?Reasons to buy- Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.- Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies.- Identify trends in interventional and observational clinical trials relevant to exosomes.Read the full report: https://www.reportlinker.com/p05627266
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: email@example.com
US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/exosome-technologies-recent-surge-in-rd-with-capricor-codiak-and-evox-therapeutics-among-key-players-300756026.html